Develops innovative allogeneic cellular therapies derived from the postpartum placenta for cancer and degenerative diseases.
Celularity Inc., headquartered in Florham Park, New Jersey, is a pioneering clinical-stage biotechnology company specializing in developing off-the-shelf placental-derived allogeneic cell therapies. The company operates through three distinct segments: Cell Therapy, Degenerative Disease, and BioBanking.
Celularity's innovative therapeutic pipeline includes several leading programs. Among these are CYCART-19, an advanced placental-derived CAR-T therapy currently in Phase I clinical trials targeting B-cell malignancies. Another key candidate is CYNK-001, an unmodified natural killer (NK) cell derived from the placenta, undergoing Phase I clinical trials for acute myeloid leukemia, glioblastoma multiforme, and COVID-19 treatment. Additionally, CYNK-101, an allogeneic genetically modified NK cell, is also in Phase I clinical trials for HER2+ gastric and gastroesophageal cancers. The company's commitment extends to innovative therapies like APPL-001 and PDA-002, placenta-derived cells in pre-clinical stages for conditions such as Crohn's disease and facioscapulohumeral muscular dystrophy, respectively.
Beyond therapeutics, Celularity engages in the sale and licensing of surgical and wound care products like Biovance and Interfyl. The company also operates a BioBanking division, specializing in the collection and storage of stem cells sourced from umbilical cords and placentas under the LifebankUSA brand. Founded in 2016, Celularity continues to advance the frontier of biotechnology with its focus on transformative cell therapies aimed at addressing cancer, immune disorders, infectious diseases, and degenerative conditions.